Myanmar Pharmacy Retail Market 2026 Analysis Guide

In 2026, the Myanmar pharmacy retail market is shaped by local affordability realities and a global shift toward self-care. In Myanmar, the pharmaceutical market was described as projected to be worth $100 to $120 million, with a population of approximately 60 million people, in reporting published by Pharmaceutical Technology. The same source notes that the healthcare system lacks funding and is primarily a self-pay system, which can push consumers toward lower-priced options. It also highlighted that, with per capita pharmaceuticals expenditure “still rather low,” generic and over-the-counter products were expected to benefit more in the short to medium term. That positioning matters for retail pharmacy operators that depend on fast-turning, accessible categories.

Global pharmacy benchmarks add context for how important retail pharmacies can be as a channel, even though these are not Myanmar figures. Grand View Research valued the global pharmacy market at USD 1.4 trillion in 2025 and projected USD 1.5 trillion in 2026, reaching USD 2.6 trillion by 2033, with a 7.6% CAGR from 2026 to 2033. In its segmentation, retail pharmacy held the largest market share at 54.4% in 2025, and prescription products represented 81.0% of revenue in 2025. For Myanmar-focused planning, these global splits do not translate directly, but they reinforce why retail formats—including chains—often become central points for both prescription dispensing and consumer-led purchases.

OTC Demand in 2026: What Retail Chains Want to Capture

OTC demand signals are especially relevant to Myanmar because the Myanmar market context points to value-seeking behavior in a self-pay environment, while OTC growth is supported by a broader global self-treatment trend. Mordor Intelligence valued the global OTC drugs market at USD 195.96 billion in 2025 and estimated USD 204.91 billion in 2026, forecasting USD 256.18 billion by 2031 at a 4.57% CAGR (2026–2031). It also reported that retail chain pharmacies captured 41.95% of OTC turnover in 2025 globally, while online pharmacies were expanding at a 9.95% CAGR over the forecast period. By category, cough, cold, and flu remedies held a 22.85% revenue share in 2025, while vitamins, minerals, and supplements were projected to grow at a 7.52% CAGR through 2031. These global shares highlight which OTC shelves often matter most for chains.

Supply mix and consumer format preferences can also influence what retail pharmacy chains prioritize. Mordor Intelligence reported tablets accounted for 38.25% of OTC sales in 2025, while gummies and chewables were the fastest-growing format at a 9.35% CAGR to 2031. By source, chemical-based OTC products retained 78.95% share in 2025, while herbal and natural alternatives had an 8.88% CAGR through 2031. Separately, GM Insights stated the OTC drugs market reached USD 187.2 billion in 2025 and is expected to record a CAGR of around 6.1% from 2026 to 2035, attributing momentum to self-medication and disease management awareness and noting that the growth of pharmacy chains and online platforms makes OTC products easier to access. For Myanmar operators, these are directional signals, not local measurements, but they can guide assortment and merchandising decisions.

Myanmar’s competitive supply backdrop, as described by Pharmaceutical Technology, also shapes chain strategy. The source stated Indian companies constitute 35% to 40% of Myanmar’s market, and it cited examples such as Ranbaxy Laboratories establishing a branch office in 1997 with more than 175 approvals to date. It also reported that Myanmar’s market favors Indian manufacturers that can offer lower-priced options compared to players from developed countries. For retail pharmacy chains, that kind of supply reality can translate into an OTC-heavy, price-sensitive front store, supported by generics and trusted brands, while still watching global channel trends where retail chains held 41.95% of OTC turnover in 2025 and online pharmacies posted a 9.95% CAGR (global, 2026–2031).

What do the sources say about Myanmar’s pharmaceutical market size?

Reporting cited by Pharmaceutical Technology described Myanmar’s pharmaceutical market as projected to be worth $100 to $120 million, with a population of approximately 60 million people.

Why does OTC matter for Myanmar retail pharmacy chains in 2026?

Pharmaceutical Technology described Myanmar’s healthcare system as primarily self-pay and noted that generic and over-the-counter drug companies could benefit in the short to medium term when per capita pharmaceuticals expenditure is low.

What share did retail chain pharmacies capture in global OTC turnover?

Mordor Intelligence reported that retail chain pharmacies captured 41.95% of global OTC turnover in 2025.

Which OTC categories and formats are highlighted by the sources?

Mordor Intelligence reported cough, cold, and flu remedies had a 22.85% revenue share in 2025, tablets held 38.25% of sales in 2025, and gummies and chewables were the fastest-growing format at a 9.35% CAGR to 2031.

How should readers interpret benchmarks when assessing the Myanmar pharmacy retail market?

The global pharmacy and OTC figures in the sources describe worldwide totals and shares, not Myanmar-specific results. They can be used as context for channel and category planning alongside Myanmar-specific notes such as market value projections and self-pay dynamics.

Talk to us for your needs in:

Let's Discuss Your Business Priorities in Myanmar

Tell us about the opportunity, challenge, investment, or strategic decision you are evaluating. Our team will help you define the right questions and determine the research and consulting support required.